Account Director, Life SciencesActive$189K–$240K

The opportunity

OpenAI's mission is to build safe artificial general intelligence (AGI) which benefits all of humanity. This long-term undertaking brings the world's best scientists, engineers, and business professionals into one lab together to accomplish this.

What you'll do

  • Manage a focused portfolio of strategic life sciences accounts across: biopharma, medtech, diagnostics, CROs, CDMOs, and life science services

  • Develop long-term account plans that map OpenAI capabilities to customer: priorities across R&D, clinical development, regulatory, manufacturing, medical affairs, commercial, and enterprise IT

  • Lead complex, multi-stakeholder sales cycles with executives, technical: leaders, scientific stakeholders, procurement, legal, privacy, security, and compliance teams

  • Identify and shape high-value AI use cases such as drug discovery support,: clinical trial operations, regulatory submissions, medical writing, pharmacovigilance, field enablement, customer operations, and enterprise knowledge workflows

  • Partner with solutions and research engineering to design pilots and: deployments that demonstrate measurable business, scientific, and operational impact

  • Collaborate with privacy, security, legal, and compliance partners to support: responsible AI deployment in regulated life sciences environments, including GxP and global data governance considerations

What they're looking for

  • Own revenue, consumption, pipeline, forecast accuracy, and expansion strategy for your accounts
  • Monitor life sciences industry trends, regulatory shifts, competitive: dynamics, and customer buying patterns to inform account strategy and the broader OpenAI go-to-market motion
  • Represent OpenAI in life sciences industry forums and customer executive: conversations, including settings such as JPM, BIO, HLTH, and targeted biopharma or medtech leadership events
  • Partner cross-functionally with marketing, partnerships, communications, and: product teams to build a repeatable life sciences go-to-market motion